KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBITDA (2018 - 2025)

Esperion Therapeutics' EBITDA history spans 8 years, with the latest figure at $61.8 million for Q4 2025.

  • For Q4 2025, EBITDA rose 390.04% year-over-year to $61.8 million; the TTM value through Dec 2025 reached -$22.7 million, up 56.17%, while the annual FY2025 figure was -$22.7 million, 56.17% up from the prior year.
  • EBITDA reached $61.8 million in Q4 2025 per ESPR's latest filing, up from -$31.3 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $61.8 million in Q4 2025 to a low of -$90.9 million in Q1 2021.
  • Average EBITDA over 5 years is -$39.3 million, with a median of -$52.4 million recorded in 2022.
  • The largest YoY upside for EBITDA was 390.04% in 2025 against a maximum downside of 166.3% in 2025.
  • A 5-year view of EBITDA shows it stood at -$65.1 million in 2021, then rose by 14.97% to -$55.4 million in 2022, then decreased by 1.71% to -$56.3 million in 2023, then skyrocketed by 62.16% to -$21.3 million in 2024, then skyrocketed by 390.04% to $61.8 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's EBITDA are $61.8 million (Q4 2025), -$31.3 million (Q3 2025), and -$12.7 million (Q2 2025).